Pulmonary arterial HTN (PAH) (idiopathic or heritable PAH & PAH associated w/ connective tissue diseases) in patients w/ WHO Functional Class III-IV symptoms to improve exercise capacity.
IV Short-term (acute) dose ranging: Initiate at 2 ng/kg/min, increased by increments of 2 ng/kg/min every ≥15 min until max haemodynamic benefit or dose‑limiting pharmacological effects are elicited. Identify lower dose if initial infusion rate is not tolerated. Long-term continuous infusion: Initiate at 4 ng/kg/min less than the max tolerated infusion rate determined during short-term dose-ranging.
View Veletri overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity. CHF arising from severe left ventricular dysfunction. Do not use chronically in patients who develop pulmonary oedema during dose‑ranging.
Decreasing pH of diluted soln w/ further dilution; restrict peripheral IV use to short duration only, using low conc. Avoid extravasation during administration; consequent risk of tissue damage due to high pH of final infusion soln. Potent pulmonary & systemic vasodilator. Potent inhibitor of platelet aggregation. Reduce dose or discontinue infusion if excessive hypotension occurs. Monitor BP & heart rate during administration. Effects on heart rate may be masked w/ concomitant drugs which affect CV reflexes. Patients w/ CAD. Elevated serum glucose levels. Pulmonary oedema during dose-ranging. Avoid abrupt w/drawal or interruption of infusion (except in life-threatening situations). May affect ability to drive & operate machinery. Discontinue breastfeeding during treatment. Elderly >65 yr. Childn.
Vasodilator effects may augment or be augmented w/ other vasodilators. Reduced thrombolytic efficacy of tissue plasminogen activator (t-PA). Increased bleeding risk w/ NSAIDs or other drugs affecting platelet aggregation. Elevated conc of digoxin.
Sign Out
